Pharmaceutical compositions of testosterone
The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, as well as methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone.
1. An injectable pharmaceutical composition consisting of:
about 200 mg/mL testosterone cypionate;
(ii) about 15 mg/mL to 30 mg/mL benzyl alcohol;
(iii) benzyl benzoate; and
(iv) cotton seed oil;
wherein the composition is sterilized and suitable for intramuscular injection; and
wherein the composition does not exhibit crystal formation for 6 months when stored at a temperature of about 10° C. to about 15° C.
2. A pre-filled syringe consisting of a liquid composition of testosterone cypionate:
wherein the composition consists of:
about 200 mg/mL testosterone cypionate;
(ii) about 15 mg/mL to 30 mg/mL benzyl alcohol;
(iii) benzyl benzoate; and
(iv) cotton seed oil;
wherein the composition is sterilized and suitable for intramuscular injection; and
wherein the composition does not exhibit crystal formation for 6 months when stored at a temperature of about 10° C. to about 15° C.
3. An injectable pharmaceutical composition consisting of:
about 200 mg/mL testosterone cypionate;
(ii) about 15 mg/mL to 30 mg/mL benzyl alcohol;
(iii) benzyl benzoate; and
(iv) cotton seed oil;
wherein the composition is sterilized and suitable for intramuscular injection; and
wherein the composition has been aged in containers for at least 48 hours at a temperature of about 20° C. to about 60° C. prior to storage, and wherein the composition does not exhibit crystal formation for 6 months when stored at a temperature of about 2° C. to about 8° C.
4. The injectable pharmaceutical composition according to claim 1 , comprising consisting of about 15 mg/mL benzyl alcohol.
5. The injectable pharmaceutical composition according to claim 1 , comprising consisting of about 20 mg/mL benzyl alcohol.
6. The injectable pharmaceutical composition according to claim 1 , comprising consisting of about 25 mg/mL benzyl alcohol.
7. The injectable pharmaceutical composition according to claim 1 , comprising consisting of 30 mg/mL benzyl alcohol.
8. The composition according to claim 2 , consisting of about 15 mg/mL benzyl alcohol.
9. The composition according to claim 2 , consisting of about 20 mg/mL benzyl alcohol.
10. The composition according to claim 2 , consisting of about 25 mg/mL benzyl alcohol.
11. The composition according to claim 2 , consisting of 30 mg/mL benzyl alcohol.
12. The composition according to claim 3 , consisting of about 15 mg/mL benzyl alcohol.
13. The composition according to claim 3 , consisting of about 20 mg/mL benzyl alcohol.
14. The composition according to claim 3 , consisting of about 25 mg/mL benzyl alcohol.
15. The composition according to claim 3 , consisting of 30 mg/mL benzyl alcohol.